Cancer Facts & Figures 2026 (American Cancer Society, 2026).
Jeha, S. et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2, 326–337 (2021).
Google ScholarÂ
Kantarjian, H., Pui, C. H. & Jabbour, E. Acute lymphocytic leukaemia. Lancet https://doi.org/10.1016/S0140-6736(25)00864-5 (2025).
Google ScholarÂ
Inaba, H. & Pui, C. H. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J. Clin. Med. https://doi.org/10.3390/jcm10091926 (2021).
Rheingold, S. R. et al. Determinants of survival after first relapse of acute lymphoblastic leukemia: a children’s oncology group study. Leukemia 38, 2382–2394 (2024).
Google ScholarÂ
Kantarjian, H. & Jabbour, E. Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. Am. J. Hematol. 100, 1205–1231 (2025).
Google ScholarÂ
Wilke, A. C. & Gokbuget, N. The role of blinatumomab in adult acute B lymphoblastic leukaemia. Br. J. Haematol. https://doi.org/10.1111/bjh.20134 (2025).
Google ScholarÂ
Kantarjian, H. et al. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer 131, e35872 (2025).
Google ScholarÂ
Sucre, O., Pamulapati, S., Muzammil, Z. & Bitran, J. Advances in therapy of adult patients with acute lymphoblastic leukemia. Cells 14, 371 (2025).
Google ScholarÂ
Foa, R. et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N. Engl. J. Med. 383, 1613–1623 (2020).
Google ScholarÂ
Litzow, M. R. et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N. Engl. J. Med. 391, 320–333 (2024).
Google ScholarÂ
Iacobucci, I., Kimura, S. & Mullighan, C. G. Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. J. Clin. Med. 10, 3792 (2021).
Google ScholarÂ
Weinberg, O. K. et al. The international consensus classification of acute leukemias of ambiguous lineage. Blood 141, 2275–2277 (2023).
Google ScholarÂ
Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36, 1720–1748 (2022).
Google ScholarÂ
Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200–1228 (2022).
Google ScholarÂ
Polonen, P. et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature 632, 1082–1091 (2024).
Google ScholarÂ
Polonen, P., Mullighan, C. G. & Teachey, D. T. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood 145, 1464–1474 (2025).
Google ScholarÂ
Paulsson, K. et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat. Genet. 47, 672–676 (2015).
Google ScholarÂ
Brady, S. W. et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat. Genet. 54, 1376–1389 (2022).
Google ScholarÂ
Paulsson, K. & Johansson, B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosom. Cancer 48, 637–660 (2009).
Google ScholarÂ
Purvis, K. et al. Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. Blood 145, 190–201 (2025).
Google ScholarÂ
Iacobucci, I. et al. Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Nat. Cancer 6, 1242–1262 (2025).
Google ScholarÂ
Aertgeerts, M. et al. Single-cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment. Hemasphere 9, e70085 (2025).
Google ScholarÂ
Gu, Z. et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat. Genet. 51, 296–307 (2019).
Google ScholarÂ
Harrison, C. J. et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br. J. Haematol. 125, 552–559 (2004).
Google ScholarÂ
Carroll, A. J. et al. Masked hypodiploidy: hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: a report from the children’s oncology group. Cancer Genet. 238, 62–68 (2019).
Google ScholarÂ
Safavi, S. & Paulsson, K. Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood 129, 420–423 (2017).
Google ScholarÂ
Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242–252 (2013).
Google ScholarÂ
Kim, R. et al. Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis. Blood Cancer Discov. 4, 134–149 (2023).
Google ScholarÂ
Paietta, E. et al. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood 138, 948–958 (2021).
Google ScholarÂ
Raimondi, S. C. et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98, 2715–2722 (2003).
Google ScholarÂ
Mullighan, C. G. et al. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood 126, 2896–2899 (2015).
Google ScholarÂ
Diaz-Flores, E. et al. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 79, 2339–2351 (2019).
Google ScholarÂ
Pariury, H. et al. Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia. Haematologica 108, 1272–1283 (2023).
Google ScholarÂ
Luskin, M. R. et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 9, 617–626 (2025).
Google ScholarÂ
Pullarkat, V. A. et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440–1453 (2021).
Google ScholarÂ
Moujalled, D. M. et al. Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Adv. 4, 2762–2767 (2020).
Google ScholarÂ
Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28, 1015–1021 (2014).
Google ScholarÂ
Li, Y. et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508, 98–102 (2014).
Google ScholarÂ
Gao, Q. et al. The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Blood 142, 711–723 (2023).
Google ScholarÂ
Moorman, A. V. et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109, 2327–2330 (2007).
Google ScholarÂ
Attarbaschi, A. et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J. Clin. Oncol. 26, 3046–3050 (2008).
Google ScholarÂ
Mori, H. et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. USA 99, 8242–8247 (2002).
Google ScholarÂ
Papaemmanuil, E. et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat. Genet. 46, 116–125 (2014).
Google ScholarÂ
Waanders, E. et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Discov. 1, 96–111 (2020).
Google ScholarÂ
Chang, T. C. et al. Genomic determinants of outcome in acute lymphoblastic leukemia. J. Clin. Oncol. 42, 3491–3503 (2024).
Google ScholarÂ
Oksa, L. et al. Genomic determinants of therapy response in ETV6::RUNX1 leukemia. Leukemia 39, 2125–2139 (2025).
Google ScholarÂ
Li, Z. et al. Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia. Nat. Commun. 16, 1153 (2025).
Google ScholarÂ
Lilljebjorn, H. et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat. Commun. 7, 11790 (2016).
Google ScholarÂ
Geng, H. et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 27, 409–425 (2015).
Google ScholarÂ
Fischer, U. et al. Genomics and drug profiling of fatal TCF3−HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat. Genet. 47, 1020–1029 (2015).
Google ScholarÂ
Zeckanovic, A. et al. Update on long-term outcomes of a cohort of patients with TCF3::HLF-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation. Haematologica 110, 1373–1378 (2025).
Google ScholarÂ
Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat. Genet. 48, 569–574 (2016).
Google ScholarÂ
Grammatico, S. et al. Lineage switch from pro-B acute lymphoid leukemia to acute myeloid leukemia in a case with t(12;17)(p13;q11)/TAF15-ZNF384 rearrangement. Leuk. Lymphoma 54, 1802–1805 (2013).
Google ScholarÂ
Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat. Genet. 48, 1481–1489 (2016).
Google ScholarÂ
Yeoh, E. J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133–143 (2002).
Google ScholarÂ
Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470–480 (2009).
Google ScholarÂ
Wang’ondu, R. W. et al. Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 39, 1595–1606 (2025).
Google ScholarÂ
Martinelli, G. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J. Clin. Oncol. 27, 5202–5207 (2009).
Google ScholarÂ
Schwab, C. et al. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia 37, 529–538 (2023).
Google ScholarÂ
Novakova, M. et al. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica 106, 2066–2075 (2021).
Google ScholarÂ
Alexander, T. B. et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562, 373–379 (2018).
Google ScholarÂ
Hirabayashi, S. et al. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia 35, 3272–3277 (2021).
Google ScholarÂ
Dickerson, K. M. et al. ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia. Blood Cancer Discov. 3, 240–263 (2022).
Google ScholarÂ
Chiaretti, S. et al. ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings. Leuk. Lymphoma 64, 483–486 (2023).
Google ScholarÂ
Zaliova, M. et al. A novel class of ZNF384 aberrations in acute leukemia. Blood Adv. 5, 4393–4397 (2021).
Google ScholarÂ
Liu, Y. F. et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 8, 173–183 (2016).
Google ScholarÂ
Suzuki, K. et al. MEF2D–BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J. Clin. Oncol. 34, 3451–3459 (2016).
Google ScholarÂ
Gu, Z. et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat. Commun. 7, 13331 (2016).
Google ScholarÂ
Cobaleda, C., Schebesta, A., Delogu, A. & Busslinger, M. Pax5: the guardian of B cell identity and function. Nat. Immunol. 8, 463–470 (2007).
Google ScholarÂ
Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758–764 (2007).
Google ScholarÂ
Passet, M. et al. PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood 133, 280–284 (2019).
Google ScholarÂ
Bastian, L. et al. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia 33, 1895–1909 (2019).
Google ScholarÂ
Fazio, G. et al. Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. Haematologica 100, e14–e17 (2015).
Google ScholarÂ
Alvey, E. N. et al. B-cell lymphoblastic leukemia/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity. Haematologica https://doi.org/10.3324/haematol.2024.286626 (2025).
Li, J. F. et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc. Natl Acad. Sci. USA 115, E11711–E11720 (2018).
Google ScholarÂ
Li, Z. et al. Genomic landscape of down syndrome-associated acute lymphoblastic leukemia. Blood 142, 172–184 (2023).
Google ScholarÂ
Kimura, S. et al. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood 139, 3519–3531 (2022).
Google ScholarÂ
Yasuda, T. et al. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. Blood https://doi.org/10.1182/blood.2021011921 (2021).
Bastian, L. et al. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment. Leukemia 36, 1676–1680 (2022).
Google ScholarÂ
Yang, M. et al. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood 136, 946–956 (2020).
Google ScholarÂ
Guarnera, L., D’Addona, M., Bravo-Perez, C. & Visconte, V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int. J. Mol. Sci. 25, 9023 (2024).
Google ScholarÂ
Kim, R. et al. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study. Blood 142, 1806–1817 (2023).
Google ScholarÂ
van der Sluis, I. M. et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N. Engl. J. Med. 388, 1572–1581 (2023).
Google ScholarÂ
Annesley, C. et al. Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL. Blood Adv. 9, 2068–2078 (2025).
Google ScholarÂ
Issa, G. C. et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J. Clin. Oncol. 43, 75–84 (2025).
Google ScholarÂ
Perner, F. et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913–919 (2023).
Google ScholarÂ
Issa, G. C. et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615, 920–924 (2023).
Google ScholarÂ
Boer, J. M. et al. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia 35, 2978–2982 (2021).
Google ScholarÂ
Hormann, F. M. et al. NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2. Haematologica 104, e455–e459 (2019).
Google ScholarÂ
Yasuda, T. et al. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. Blood 139, 1850–1862 (2022).
Google ScholarÂ
Horns, J. M. et al. IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma. Blood https://doi.org/10.1182/blood.2025031047 (2026).
Bomken, S. et al. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. Haematologica 108, 717–731 (2023).
Google ScholarÂ
Foa, R. et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J. Clin. Oncol. 42, 881–885 (2024).
Google ScholarÂ
Slayton, W. B. et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J. Clin. Oncol. 36, 2306–2314 (2018).
Google ScholarÂ
Short, N. J. et al. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J. Hematol. Oncol. 18, 55 (2025).
Google ScholarÂ
Iacobucci, I. et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114, 2159–2167 (2009).
Google ScholarÂ
Hovorkova, L. et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood 129, 2771–2781 (2017).
Google ScholarÂ
Kamoda, Y. et al. Philadelphia chromosome-positive acute lymphoblastic leukemia is separated into two subgroups associated with survival by BCR-ABL fluorescence in situ hybridization of segmented cell nuclei: report from a single institution. Acta Haematol. 136, 157–166 (2016).
Google ScholarÂ
Chen, Z. et al. Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. Leuk. Lymphoma 61, 2831–2838 (2020).
Google ScholarÂ
Kim, J. C. et al. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. Nat. Genet. 55, 1186–1197 (2023).
Google ScholarÂ
Bastian, L. et al. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL. Blood 143, 1391–1398 (2024).
Google ScholarÂ
Kim, R. et al. Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: a GRAAPH-2014 study. J. Clin. Oncol. 42, 3140–3150 (2024).
Google ScholarÂ
Nagel, I. et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130, 2027–2031 (2017).
Google ScholarÂ
Short, N. J. et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am. J. Hematol. 98, 1196–1203 (2023).
Google ScholarÂ
Cazzaniga, G. et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica 103, 107–115 (2018).
Google ScholarÂ
Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005–1015 (2014).
Google ScholarÂ
Roberts, K. G. et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J. Clin. Oncol. 35, 394–401 (2017).
Google ScholarÂ
Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125–134 (2009).
Google ScholarÂ
Roberts, K. G. et al. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition. Blood 132, 861–865 (2018).
Google ScholarÂ
Nardi, V. et al. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 4, 106–111 (2020).
Google ScholarÂ
Tran, T. H. & Tasian, S. K. How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults. Blood 145, 20–34 (2025).
Google ScholarÂ
Tanasi, I. et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood 134, 1351–1355 (2019).
Google ScholarÂ
van Outersterp, I. et al. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain. Blood 143, 2178–2189 (2024).
Google ScholarÂ
Zhao, Y. et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood 137, 471–484 (2021).
Google ScholarÂ
Aldoss, I. et al. Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica 110, 1105–1114 (2025).
Google ScholarÂ
Ding, Y. Y. et al. Targeting senescent stemlike subpopulations in Philadelphia chromosome-like acute lymphoblastic leukemia. Blood 145, 1195–1210 (2025).
Google ScholarÂ
Iacobucci, I. & Papayannidis, C. Approach to BCR::ABL1-like acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 25, 13–22 (2025).
Google ScholarÂ
Bene, M. C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9, 1783–1786 (1995).
Google ScholarÂ
Coustan-Smith, E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147–156 (2009).
Google ScholarÂ
O’Connor, D. et al. Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL. Blood 143, 933–937 (2024).
Google ScholarÂ
Rahman, S. et al. Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia. Blood 144, 2319–2326 (2024).
Google ScholarÂ
Haydu, J. E. et al. An activating intragenic deletion in NOTCH1 in human T-ALL. Blood 119, 5211–5214 (2012).
Google ScholarÂ
Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261–18266 (2006).
Google ScholarÂ
Ferrando, A. NOTCH mutations as prognostic markers in T-ALL. Leukemia 24, 2003–2004 (2010).
Google ScholarÂ
Al Kuwari, H. et al. NOTCH1 mutation status as a prognostic biomarker in T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis. BMC Cancer 25, 1820 (2025).
Google ScholarÂ
Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211–1218 (2017).
Google ScholarÂ
Montefiori, L. E. et al. Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia. Cancer Discov. 11, 2846–2867 (2021).
Google ScholarÂ
Di Giacomo, D. et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. Blood 138, 773–784 (2021).
Google ScholarÂ
Di Giacomo, D. et al. Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia. Blood https://doi.org/10.1182/blood.2025031402 (2026).
Google ScholarÂ
Mimura, K. et al. BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL. Blood https://doi.org/10.1182/blood.2025031466 (2026).
Google ScholarÂ
Wang, Q. et al. Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia. Am. J. Hematol. 98, 66–78 (2023).
Google ScholarÂ
Montefiori, L. E. et al. Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia. Blood 146, 2350–2356 (2025).
Google ScholarÂ
Tirtakusuma, R. et al. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. Blood 140, 1875–1890 (2022).
Google ScholarÂ
Hetzel, S. et al. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat. Cancer 3, 768–782 (2022).
Google ScholarÂ
Roman-Gomez, J. et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 20, 1445–1448 (2006).
Google ScholarÂ
Borssen, M. et al. Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS ONE 8, e65373 (2013).
Google ScholarÂ
Haider, Z. et al. An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression. Cancer Med. 8, 311–324 (2019).
Google ScholarÂ
Borssen, M. et al. DNA methylation adds prognostic value to minimal residual disease status in pediatric T-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 63, 1185–1192 (2016).
Google ScholarÂ
Kimura, S. et al. DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes. Leukemia 34, 1163–1168 (2020).
Google ScholarÂ
Roels, J. et al. Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Cancer Discov. 1, 274–289 (2020).
Google ScholarÂ
Liapodimitri, A. et al. Mapping the dynamic DNA methylation landscape in pre-B ALL from diagnosis to relapse reveals a role for aberrant PRC2 regulation. Blood 144, 4127–4127 (2024).
Google ScholarÂ
Stumpel, D. J. et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114, 5490–5498 (2009).
Google ScholarÂ
Steinicke, T. L. et al. Rapid epigenomic classification of acute leukemia. Nat. Genet. 57, 2456–2467 (2025).
Google ScholarÂ
Kramer, A. C. et al. Dnmt3a regulates T-cell development and suppresses T-ALL transformation. Leukemia 31, 2479–2490 (2017).
Google ScholarÂ
Bond, J. et al. DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica 104, 1617–1625 (2019).
Google ScholarÂ
Szarzynska-Zawadzka, B. et al. Cost-effective screening of DNMT3A coding sequence identifies somatic mutation in pediatric T-cell acute lymphoblastic leukemia. Eur. J. Haematol. 99, 514–519 (2017).
Google ScholarÂ
Bensberg, M. et al. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 118, e2110758118 (2021).
Google ScholarÂ
Poole, C. J., Lodh, A., Choi, J. H. & van Riggelen, J. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. Epigenetics Chromatin 12, 41 (2019).
Google ScholarÂ
Simonin, M. et al. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. J. Hematol. Oncol. 14, 74 (2021).
Google ScholarÂ
Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235–239 (2011).
Google ScholarÂ
Li, J. et al. PRC2 inhibitors overcome glucocorticoid resistance driven by NSD2 mutation in pediatric acute lymphoblastic leukemia. Cancer Discov. 12, 186–203 (2022).
Google ScholarÂ
Mar, B. G. et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun. 5, 3469 (2014).
Google ScholarÂ
Van der Meulen, J. et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood 125, 13–21 (2015).
Google ScholarÂ
Benyoucef, A. et al. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. Genes. Dev. 30, 508–521 (2016).
Google ScholarÂ
Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513–517 (2014).
Google ScholarÂ
Kloetgen, A. et al. Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia. Nat. Genet. 52, 388–400 (2020).
Google ScholarÂ
Barnett, K. R. et al. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genom. 3, 100442 (2023).
Google ScholarÂ
Narang, S. et al. Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia. Nat. Commun. 15, 7425 (2024).
Google ScholarÂ
Wang, H. et al. Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia. Nat. Commun. 14, 6792 (2023).
Google ScholarÂ
Ford, A. M. et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363, 358–360 (1993).
Google ScholarÂ
Ford, A. M. et al. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc. Natl Acad. Sci. USA 95, 4584–4588 (1998).
Google ScholarÂ
Hein, D. et al. The preleukemic TCF3–PBX1 gene fusion can be generated in utero and is present in approximately 0.6% of healthy newborns. Blood 134, 1355–1358 (2019).
Google ScholarÂ
Cazzaniga, G. et al. Developmental origins and impact of BCR–ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood 118, 5559–5564 (2011).
Google ScholarÂ
Yagi, T. et al. Detection of clonotypic IGH and TCR rearrangements in the neonatal blood spots of infants and children with B-cell precursor acute lymphoblastic leukemia. Blood 96, 264–268 (2000).
Google ScholarÂ
Greaves, M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat. Rev. Cancer 18, 471–484 (2018).
Google ScholarÂ
Schafer, D. et al. Five percent of healthy newborns have an ETV6–RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood 131, 821–826 (2018).
Google ScholarÂ
Hein, D., Borkhardt, A. & Fischer, U. Insights into the prenatal origin of childhood acute lymphoblastic leukemia. Cancer Metastasis Rev. 39, 161–171 (2020).
Google ScholarÂ
de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24–37 (2006).
Google ScholarÂ
Kinlen, L. Childhood leukaemia, nuclear sites, and population mixing. Br. J. Cancer 104, 12–18 (2011).
Google ScholarÂ
Mullighan, C. G. et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008).
Google ScholarÂ
Swaminathan, S. et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat. Immunol. 16, 766–774 (2015).
Google ScholarÂ
Martin-Lorenzo, A. et al. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility. Cancer Discov. 5, 1328–1343 (2015).
Google ScholarÂ
RodrÃguez-Hernandez, G. et al. Infection exposure promotes ETV6–RUNX1 precursor B-cell leukemia via impaired H3K4 demethylases. Cancer Res. 77, 4365–4377 (2017).
Google ScholarÂ
Fidanza, M. et al. Inhibition of precursor B-cell malignancy progression by Toll-like receptor ligand-induced immune responses. Leukemia 30, 2116–2119 (2016).
Google ScholarÂ
Moriyama, T., Relling, M. V. & Yang, J. J. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 125, 3988–3995 (2015).
Google ScholarÂ
Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226–1231 (2013).
Google ScholarÂ
Churchman, M. L. et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell 33, 937–948 e938 (2018).
Google ScholarÂ
Rampersaud, E. et al. Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Adv. 3, 1039–1046 (2019).
Google ScholarÂ
Xu, H. et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 30, 751–757 (2012).
Google ScholarÂ
Perez-Andreu, V. et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 45, 1494–1498 (2013).
Google ScholarÂ
Stanulla, M. et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293, 1485–1489 (2005).
Google ScholarÂ
Relling, M. V., Pui, C. H., Cheng, C. & Evans, W. E. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107, 843–844 (2006).
Google ScholarÂ
Yang, S. K. et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 46, 1017–1020 (2014).
Google ScholarÂ
Abrams, M. T., Robertson, N. M., Yoon, K. & Wickstrom, E. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J. Biol. Chem. 279, 55809–55817 (2004).
Google ScholarÂ
Beder, T. et al. The gene expression classifier ALLCatchR identifies B-cell precursor all subtypes and underlying developmental trajectories across age. Hemasphere 7, e939 (2023).
Google ScholarÂ
Xu, J. et al. A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia. Nat. Cancer 6, 102–122 (2025).
Google ScholarÂ
Costea, J. et al. Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia. Nat. Commun. 16, 5413 (2025).
Google ScholarÂ
Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380 (2008).
Google ScholarÂ
Tzoneva, G. et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 553, 511–514 (2018).
Google ScholarÂ
Evensen, N. A. et al. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica 103, 830–839 (2018).
Google ScholarÂ
Vanner, R. J. et al. Multiomic profiling of central nervous system leukemia identifies mRNA translation as a therapeutic target. Blood Cancer Discov. 3, 16–31 (2022).
Google ScholarÂ
Lee, B. J. et al. CD19-directed immunotherapy use in KMT2A-rearranged acute leukemia: a case report and literature review of increased lymphoid to myeloid lineage switch. Am. J. Hematol. 97, E439–E443 (2022).
Google ScholarÂ
Haddox, C. L. et al. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J. 7, e607 (2017).
Google ScholarÂ
Rossi, J. G. et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am. J. Hematol. 87, 890–897 (2012).
Google ScholarÂ
Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504–1506 (2018).
Google ScholarÂ
Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015).
Google ScholarÂ
Asnani, M. et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia 34, 1202–1207 (2020).
Google ScholarÂ
Braig, F. et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129, 100–104 (2017).
Google ScholarÂ
Huo, Y. et al. Blinatumomab-induced T cell activation at single cell transcriptome resolution. BMC Genomics 22, 145 (2021).
Google ScholarÂ
Ruella, M. & Maus, M. V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 14, 357–362 (2016).
Google ScholarÂ
Cao, L., Leclercq-Cohen, G., Klein, C., Sorrentino, A. & Bacac, M. Mechanistic insights into resistance mechanisms to T cell engagers. Front. Immunol. 16, 1583044 (2025).
Google ScholarÂ
Duell, J. et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 31, 2181–2190 (2017).
Google ScholarÂ
Zheng, S. et al. Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies. Blood Cancer Discov. 3, 103–115 (2022).
Google ScholarÂ
Zhao, Y. et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood 144, 61–73 (2024).
Google ScholarÂ
Escherich, C. S. et al. DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood 145, 1182–1194 (2025).
Google ScholarÂ
Escherich, C. S. et al. Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin. Blood 146, 471–481 (2025).
Google ScholarÂ
Domizi, P. et al. IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. Nat. Commun. 16, 3800 (2025).
Google ScholarÂ
Gokbuget, N. et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 143, 1891–1902 (2024).
Google ScholarÂ
Short, N. J. et al. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 9, 1442–1451 (2025).
Google ScholarÂ
Stanulla, M. et al. IKZF1(plus) defines a new minimal residual Disease-Dependent Very-Poor prognostic profile in pediatric B-Cell precursor acute lymphoblastic leukemia. J. Clin. Oncol. 36, 1240–1249 (2018).
Google ScholarÂ
Zhong, X. et al. Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial. Blood 146, 31 (2025).
Google ScholarÂ
Simonin, M. et al. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients. Blood 144, 1570–1580 (2024).
Google ScholarÂ
Chen, X. & Wood, B. L. How do we measure MRD in ALL and how should measurements affect decisions. Re: treatment and prognosis? Best Pract. Res. Clin. Haematol. 30, 237–248 (2017).
Google ScholarÂ
Theunissen, P. et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129, 347–357 (2017).
Google ScholarÂ
van Dongen, J. J. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 1901–1928 (1999).
Google ScholarÂ
Pfeifer, H. et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia 33, 1910–1922 (2019).
Google ScholarÂ
van der Velden, V. H. J. et al. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines. Leukemia 38, 1315–1322 (2024).
Google ScholarÂ
Bruggemann, M. et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 24, 521–535 (2010).
Google ScholarÂ
Kotrova, M. et al. NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation. Blood 146, 585–589 (2025).
Google ScholarÂ
Faham, M. et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120, 5173–5180 (2012).
Google ScholarÂ
Short, N. J. et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 6, 4006–4014 (2022).
Google ScholarÂ
Svaton, M. et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood 141, 529–533 (2023).
Google ScholarÂ
Wood, B. et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 131, 1350–1359 (2018).
Google ScholarÂ
O’Connor, D. et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J. Clin. Oncol. 36, 34–43 (2018).
Google ScholarÂ
Pui, C. H. et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia 31, 333–339 (2017).
Google ScholarÂ
Burmeister, T. et al. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia. Leukemia 38, 1600–1603 (2024).
Google ScholarÂ
van der Velden, V. H. et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 16, 1432–1436 (2002).
Google ScholarÂ
Muffly, L. et al. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv. 5, 3147–3151 (2021).
Google ScholarÂ
Iacobucci, I. Age shapes the immunogenetic fingerprint of ALL. Blood 146, 525–526 (2025).
Google ScholarÂ
Kilgour, E., Rothwell, D. G., Brady, G. & Dive, C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 37, 485–495 (2020).
Google ScholarÂ
Lim, J. K., Kuss, B. & Talaulikar, D. Role of cell-free DNA in haematological malignancies. Pathology 53, 416–426 (2021).
Google ScholarÂ
Lei, S. et al. Genomic profiling of circulating tumor DNA for childhood cancers. Leukemia 39, 420–430 (2025).
Google ScholarÂ
Sampathi, S. et al. Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia. Front. Oncol. 12, 958673 (2022).
Google ScholarÂ
Schroers-Martin, J. G. & Alizadeh, A. A. Cell-free DNA in hematologic malignancies. JCO Oncol. Pract. 20, 1491–1499 (2024).
Google ScholarÂ
Jeong, H. et al. Functional analysis of structural variants in single cells using Strand-seq. Nat. Biotechnol. 41, 832–844 (2023).
Google ScholarÂ
Schmidt, B. et al. ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia. Blood Adv. 6, 4093–4097 (2022).
Google ScholarÂ
Hu, Z. et al. MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia. Haematologica 109, 1741–1754 (2024).
Google ScholarÂ
Krali, O. et al. Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia. NPJ Precis. Oncol. 7, 131 (2023).
Google ScholarÂ
Laukkanen, S. et al. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J. 7, e604 (2017).
Google ScholarÂ
Gocho, Y. et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat. Cancer 2, 284–299 (2021).
Google ScholarÂ
Inaba, H., Azzato, E. M. & Mullighan, C. G. Integration of next-generation sequencing to treat acute lymphoblastic leukemia with targetable lesions: the St. Jude Children’s Research Hospital approach. Front. Pediatr. 5, 258 (2017).
Google ScholarÂ
Duncavage, E. J. et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood 140, 2228–2247 (2022).
Google ScholarÂ
